TY - JOUR
T1 - Origins of timed cancer treatment
T2 - Early marker rhythm-guided individualized chronochemotherapy
AU - Halberg, Franz
AU - Prem, Konald
AU - Halberg, Francine
AU - Norman, Catherine
AU - Cornelissen-Guillaume, Germaine G
PY - 2006
Y1 - 2006
N2 - A 21-year old patient who presented in 1973 with a rare and highly malignant ovarian endodermal sinus tumor with spillage into the peritoneal cavity is alive and well today after receiving chronochemotherapy. During the first four courses of treatment, medications were given at different circadian stages. Complete blood counts and marker variables such as mood, vigor, nausea, and temperature were monitored around the clock and analyzed by cosinor to seek times of highest tolerance. Remaining treatment courses were administered at a time corresponding to the patient's best drug tolerance, rather than extrapolating the timing of optimal cyclophosphamide administration from also-implemented parallel laboratory studies on mice. Notwithstanding remaining hurdles in bringing chronochemotherapy to the clinic for routine care, merits of marker rhythm-guided chronotherapy documented in this and other case reports have led to the doubling of the two-year disease-free survival of patients with large perioral tumors in a clinical trial.
AB - A 21-year old patient who presented in 1973 with a rare and highly malignant ovarian endodermal sinus tumor with spillage into the peritoneal cavity is alive and well today after receiving chronochemotherapy. During the first four courses of treatment, medications were given at different circadian stages. Complete blood counts and marker variables such as mood, vigor, nausea, and temperature were monitored around the clock and analyzed by cosinor to seek times of highest tolerance. Remaining treatment courses were administered at a time corresponding to the patient's best drug tolerance, rather than extrapolating the timing of optimal cyclophosphamide administration from also-implemented parallel laboratory studies on mice. Notwithstanding remaining hurdles in bringing chronochemotherapy to the clinic for routine care, merits of marker rhythm-guided chronotherapy documented in this and other case reports have led to the doubling of the two-year disease-free survival of patients with large perioral tumors in a clinical trial.
KW - Chronotherapy
KW - Circadian
KW - Malignant ovarian endodermal sinus tumor (yolk sac carcinoma)
KW - Marker rhythm
KW - Tumor marker
UR - http://www.scopus.com/inward/record.url?scp=33846049655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846049655&partnerID=8YFLogxK
M3 - Article
C2 - 17228525
AN - SCOPUS:33846049655
SN - 1359-4117
VL - 6
SP - 55
EP - 61
JO - Journal of Experimental Therapeutics and Oncology
JF - Journal of Experimental Therapeutics and Oncology
IS - 1
ER -